RG1068 (Synthetic Human Secretin)
Phase 3Small molecule
RG1068 (Synthetic Human Secretin) is one of 83 small molecule programs targeting Chronic Pancreatitis. It is currently in Phase 3.
2
Indications
7
Total Trials
0
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
109 competitors in Autism
#DrugCompanyPhaseTrials
1Pitocin
RRetrophin
Phase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Bumex
VValidus Pharmaceuticals
Phase 3
Zoloft
VViatris Specialty LLC
Phase 3
Reminyl
WWim Janssens
Phase 3
Latuda
SSunovion Respiratory Development Inc.
Phase 3
Luvox
SSolvay Pharmaceuticals
Phase 3
Paliperidone ER
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Folinic Acid
RochePhase 3
Kuvan
BioMarin PharmaceuticalPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Autism2 trials
Neoplasms1 trial
Obsessive-Compulsive Disorder1 trial
Safety and Efficacy1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMassachusetts General Hospital